INTRODUCTION

Multiple myeloma (MM) prognosis worsens once patients become triple-class exposed (TCE) to at least one treatment in each class: immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies.

METHODS

We conducted a retrospective study using the Cancer Analysis System database to assess characteristics, treatment patterns, and clinical outcomes for adults diagnosed with MM between 2014 and 2020. The main cohort included patients ≥18 years-old diagnosed with incident MM (including TCE patients) who had at least one record of systemic anticancer therapy treatment within 30 days prior to, on, or any time after their diagnosis.

RESULTS

The main cohort comprised 14,990 patients, predominantly white and male, with a median age at diagnosis of 71 years. Of these, 848 (5.6%) became TCE. In the main cohort ( = 14,990), 57.2% of patients received only one line of therapy, and >50% of all first-line regimens included bortezomib. Median overall survival (OS) from diagnosis was 51.5 months. After becoming TCE ( = 848), median OS was 13.2 months and median time to next treatment or death was 5.7 months.

CONCLUSIONS

This study provides current evidence on real-world OS and management for patients with MM in England, including those who become TCE.